Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SUPRIYA

SUPRIYA

Supriya Lifescience Limited
Micro-capPharma ↗

What the six lenses say about SUPRIYA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹909.1
2026-09-08
VWAP · 1Y anchor
₹820
+10.9% from VWAP
P/E · TTM
—
no TTM EPS
52-week range
71%
position low→high
RSI(14)
66
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SUPRIYA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD660›

The actual numbers

Price vs VWAP (1y)+10.9%
EMA trend stackMixed
Price vs 200-EMA+17.5%
Price vs 50-EMA+8.8%
RSI(14)66
RS vs Nifty 500 · 3M-5.5%
RS vs sector · 3M-11.6%
52-week range71%
Volume vs 30d avg0.73×
Volume vs 60d avg0.69×
ATR(14) · volatility43.1
Bollinger width · vol contraction0.155
FundamentalD1087›

The actual numbers

Operating margin35.7%
Net margin26.0%
Revenue growth · YoY+20.9%
EPS growth · YoY+44.8%

Full 8-quarter history in the financials table below.

ValuationD317›

The actual numbers

52-week range71%
CatalystD537›

The actual numbers

Earnings & momentum45
Capital actions12
Governance55

Every filing in the corporate-announcements panel below.

FlowD860›

The actual numbers

Promoter holding68.3%
Delivery · 30d avg45.4%
Up/down-day asymmetry-2.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D6 + D8 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · High
60
Conviction score 60/100 · avg-decile strength 7.0/10
Conviction score60/100›
TechnicalD6›
FundamentalD10›
ValuationD3›
CatalystD5›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+7.1pp
+15.1pp
+5.5pp
-3.9pp
+47.5pp
+43.4pp
Nifty 500
Broad-market baseline
+7.0pp
+15.1pp
+4.5pp
-5.5pp
+41.8pp
+38.2pp
Sector
Own-sector index
—
—
+1.6pp
-11.6pp
+28.7pp
+17.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SUPRIYA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
909.10+56.25

Relative strength

RS vs baseline · rebased to 100

SUPRIYA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
151.68+9.98

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

No quarterly financials available.

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 2 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Sep '26
    HIGHearnings
    Clarification - Financial Results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds SUPRIYA

Mutual funds holding SUPRIYA (7)

FundWeightAUM ₹crGrade
Abakkus Flexi Cap Reg Gr0.73%6,338
WhiteOak Capital Phrm and Hlthcr Reg Gr0.60%825
ITI Large & Mid Cap Reg Gr1.50%740
ITI ELSS Tax Saver Reg Gr1.74%455
ITI Pharma and Healthcare Reg Gr0.92%263
Quantum Small Cap Reg Gr3.64%254
Samco Small Cap Reg Gr1.14%170

ETFs holding SUPRIYA (0)

No tracked ETF holds SUPRIYA ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma